Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Clear cell renal cell carcinoma, drawn from the whole corpus: 19 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No validated biomarker chooses between immunotherapy doublets.
Most metastatic patients still progress within two to three years.
Nothing recorded yet.
Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Overtreatment of small renal masses versus the risk of surveillance.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 13 changes by month →When this page itself was last checked or edited.
ccRCC after ≥2 lines; VHL-associated tumours; 12 Feb 2025 (conditional)
DFS HR 0.
A milestone in how this cancer is treated.
OS HR 0.
A milestone in how this cancer is treated.